Measuring disease activity in COPD: is clinically important deterioration the answer?
CID
COPD
Clinically important deterioration
Deterioration
Health status
Long-term outcome
Lung function
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
02 Jun 2020
02 Jun 2020
Historique:
received:
26
11
2019
accepted:
05
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
7
4
2021
Statut:
epublish
Résumé
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), personalized clinical management is key to optimizing patient outcomes. Important treatment goals include minimizing disease activity and preventing disease progression; however, quantification of these components remains a challenge. Growing evidence suggests that decline over time in forced expiratory volume in 1 s (FEV
Identifiants
pubmed: 32487202
doi: 10.1186/s12931-020-01387-z
pii: 10.1186/s12931-020-01387-z
pmc: PMC7265253
doi:
Substances chimiques
Bronchodilator Agents
0
Muscarinic Antagonists
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
134Subventions
Organisme : GSK
ID : Not Applicable
Commentaires et corrections
Type : ErratumIn
Références
Agusti A, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11:122.
pubmed: 20831787
pmcid: 2944278
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). Available at http://goldcopd.org/ . Accessed Jan 2020. 2020.
Agusti A, Gea J, Faner R. Biomarkers, the control panel and personalized COPD medicine. Respirology. 2016;21(1):24–33.
pubmed: 26172306
Singh D, et al. Current controversies in the pharmacological treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(5):541–9.
pubmed: 27585383
Singh D, et al. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–24.
pubmed: 27445468
pmcid: 4928660
Halpin DM, Tashkin DP. Defining disease modification in chronic obstructive pulmonary disease. COPD. 2009;6(3):211–25.
pubmed: 19811377
Food and Drug Administration (FDA) Chronic obstructive pulmonary disease: developing drugs for treatment. Guidance for Industry. 2016.
Oga T, et al. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med. 2007;101(1):146–53.
pubmed: 16713225
Kostikas K, et al. Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study. ERJ Open Res. 2019;5(1):00243-2018.
pubmed: 30815470
pmcid: 6387992
Casanova C, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med. 2011;184(9):1015–21.
pubmed: 21836135
Vestbo J, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med. 2011;365(13):1184–92.
pubmed: 21991892
Vestbo J, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–73.
pubmed: 18216052
Sanchez-Salcedo P, et al. Disease progression in young patients with COPD: rethinking the fletcher and Peto model. Eur Respir J. 2014;44(2):324–31.
pubmed: 24696115
Lange P, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med. 2015;373(2):111–22.
pubmed: 26154786
Csikesz NG, Gartman EJ. New developments in the assessment of COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis. 2014;9:277–86.
pubmed: 24600220
pmcid: 3942111
Vestbo J, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011;5(1):44–9.
pubmed: 21159140
Casanova C, et al. Longitudinal assessment in COPD patients: multidimensional variability and outcomes. Eur Respir J. 2014;43(3):745–53.
pubmed: 24072210
Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11:79.
pubmed: 20565728
pmcid: 2902430
Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(4):822–32.
pubmed: 16585091
Oga T, et al. Multidimensional analyses of long-term clinical courses of asthma and chronic obstructive pulmonary disease. Allergol Int. 2010;59(3):257–65.
pubmed: 20657164
Celli BR, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–12.
pubmed: 14999112
Esteban C, et al. A simple score for assessing stable chronic obstructive pulmonary disease. QJM. 2006;99(11):751–9.
pubmed: 17030529
Esteban C, et al. Development of a decision tree to assess the severity and prognosis of stable COPD. Eur Respir J. 2011;38(6):1294–300.
pubmed: 21565913
Jones RC, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE index. Am J Respir Crit Care Med. 2009;180(12):1189–95.
pubmed: 19797160
Azarisman MS, et al. The SAFE (SGRQ score, air-flow limitation and exercise tolerance) index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad Med J. 2007;83(981):492–7.
pubmed: 17621621
pmcid: 2600092
van Dijk WD, et al. Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res. 2011;12:151.
pubmed: 22082049
pmcid: 3228786
Mahler DA, Criner GJ. Assessment tools for chronic obstructive pulmonary disease: do newer metrics allow for disease modification? Proc Am Thorac Soc. 2007;4(7):507–11.
pubmed: 17878462
Donaldson GC, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–52.
pubmed: 1746193
pmcid: 1746193
Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8–11.
pubmed: 16113462
Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127(6):1952–9.
pubmed: 15947307
Schmidt SA, et al. The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study. BMJ Open. 2014;4(12):e006720.
pubmed: 25526796
pmcid: 4275660
Tockman MS, et al. Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med. 1995;151(2 Pt 1):390–8.
pubmed: 7842197
Jones PW, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44(5):1156–65.
pubmed: 25234803
Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–24.
pubmed: 17136971
Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–9.
pubmed: 17136966
Wilke S, et al. One-year change in health status and subsequent outcomes in COPD. Thorax. 2015;70(5):420–5.
pubmed: 25782757
Anzueto AR, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19(1):121.
pubmed: 29925383
pmcid: 6011394
Anzueto AR, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325–37.
pubmed: 28496316
pmcid: 5422319
D'Urzo A, et al. Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials. NPJ Prim Care Respir Med. 2018;28(1):18.
pubmed: 29795478
pmcid: 5967309
Greulich T, et al. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study. Int J Chron Obstruct Pulmon Dis. 2018;13:1229–37.
pubmed: 29713156
pmcid: 5909796
Maleki-Yazdi MR, et al. Assessing short-term deterioration in maintenance-naive patients with COPD receiving Umeclidinium/Vilanterol and Tiotropium: a pooled analysis of three randomized trials. Adv Ther. 2017;33(12):2188–99.
pubmed: 27796912
Naya I, et al. Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Res. 2018;4(4):00047-2018.
pubmed: 30302335
pmcid: 6168763
Naya IP, et al. Preventing clinically important deterioration of COPD with addition of Umeclidinium to inhaled corticosteroid/long-acting beta2-agonist therapy: an integrated post hoc analysis. Adv Ther. 2018;35(10):1626–38.
pubmed: 30191464
pmcid: 6182634
Singh D, et al. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017;18(1):106.
pubmed: 28558833
pmcid: 5450266
Singh D, et al. Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA. Int J Chron Obstruct Pulmon Dis. 2019;14:531–46.
pubmed: 30880943
pmcid: 6400232
Maltais F, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respir Res. 2019;20(1):238.
pubmed: 31666084
pmcid: 6821007
Calverley PM, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.
pubmed: 17314337
Naya IP, et al. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res. 2018;19(1):222.
pubmed: 30453972
pmcid: 6245880
Pavord ID, et al. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):21–30.
pubmed: 26937187
pmcid: 4764047
Wilkinson TMA, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169(12):1298–303.
Lipson DA, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–46.
pubmed: 28375647
Donohue JF, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–46.
pubmed: 23830094
Maleki-Yazdi MR, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752–60.
pubmed: 25458157
Wedzicha JA, et al. Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34.
pubmed: 27181606
Kaul S, Diamond GA. Trial and error: how to avoid commonly encountered limitations of published clinical trials. J Am Coll Cardiol. 2010;55(5):415–27.
pubmed: 20117454
Schermer TR, et al. Point of care microspirometry to facilitate the COPD diagnostic process in primary care: a clustered randomised trial. NPJ Prim Care Respir Med. 2018;28(1):17.
pubmed: 29789607
pmcid: 5964085
Decramer M, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–86.
pubmed: 24835833